AusCann Builds Momentum with Achievement of Major Milestones in H1 FY18
Highlights
-
AusCann aims to provide Australia and select international markets with high-quality, economical and clinically-validated cannabinoid medicines
-
AusCann achieved many important milestones across its strategic partnerships, medical outreach program, Chilean and Australian operations, and the regulatory landscape
-
AusCann ended the half year with approximately $12.3 million in cash and is well- funded heading into H2 FY18
For further information please download PDF attached:
Download this document
